Karyopharm Therapeutics Inc Financials
Karyopharm Therapeutics Inc (KPTI) reported $146.1M in revenue for fiscal year 2025, up 0.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Flat revenue and heavy expense cuts are shrinking the operating loss, but financing costs now dominate the economics.
Revenue stayed near$146M over multiple years, yet operating margin ended at-62.1% ; the improvement came from a smaller cost base, not from a larger business. But interest expense reached$45.8M as liabilities climbed to$401.3M , which is why net loss worsened even as the operating loss narrowed.
Both SG&A and R&D were trimmed over recent years, which explains why operating losses eased even without revenue growth. Because capital spending was essentially zero, free cash flow matched operating cash flow at
The current ratio fell to 1.1x and cash was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Karyopharm Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Karyopharm Therapeutics Inc, and counted as zero in the overall score.
Not available for Karyopharm Therapeutics Inc, and counted as zero in the overall score.
Karyopharm Therapeutics Inc scores -23.95, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($43.5M) relative to total liabilities ($401.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Karyopharm Therapeutics Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Karyopharm Therapeutics Inc reported a net loss of $196.0M while operations used $75.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Karyopharm Therapeutics Inc reported an operating loss of $90.7M against $45.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Karyopharm Therapeutics Inc generated $146.1M in revenue in fiscal year 2025. This represents an increase of 0.6% from the prior year.
Karyopharm Therapeutics Inc's EBITDA was -$90.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.1% from the prior year.
Karyopharm Therapeutics Inc reported -$196.0M in net income in fiscal year 2025. This represents a decrease of 156.5% from the prior year.
Karyopharm Therapeutics Inc earned -$17.93 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Karyopharm Therapeutics Inc recorded an outflow of $75.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 40.9% from the prior year.
Karyopharm Therapeutics Inc held $60.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Karyopharm Therapeutics Inc's operating margin was -62.1% in fiscal year 2025, reflecting core business profitability. This is up 20.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Karyopharm Therapeutics Inc invested $125.6M in research and development in fiscal year 2025. This represents a decrease of 12.3% from the prior year.
Karyopharm Therapeutics Inc reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
KPTI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.6M | $146.1M+0.6% | $145.2M-0.5% | $146.0M-7.0% | $157.1M-25.1% | $209.8M+94.1% | $108.1M+164.3% | $40.9M+34.8% | $30.3M+1790.1% | $1.6M+942.2% | $154K-38.4% | $250K+9.2% | $229K-40.8% | $387K-39.0% | $634K+317.1% | $152K |
| R&D Expenses | $121.0M | $125.6M-12.3% | $143.2M+3.2% | $138.8M-6.7% | $148.7M-7.6% | $160.8M+6.6% | $150.8M+23.3% | $122.3M-24.2% | $161.4M+50.4% | $107.3M+23.4% | $86.9M-11.1% | $97.7M+62.6% | $60.1M+111.3% | $28.5M | N/A | $8.6M |
| SG&A Expenses | $102.0M | $105.2M-8.9% | $115.4M-12.5% | $131.9M-9.3% | $145.4M+1.1% | $143.8M+13.8% | $126.4M+19.9% | $105.4M+115.8% | $48.8M+96.4% | $24.9M+3.9% | $23.9M+11.0% | $21.6M+35.3% | $15.9M+171.0% | $5.9M+142.3% | $2.4M+32.0% | $1.8M |
| Operating Income | -$82.3M | -$90.7M+24.1% | -$119.4M+7.8% | -$129.5M+8.9% | -$142.2M-44.7% | -$98.3M+42.8% | -$171.8M+9.2% | -$189.3M-5.2% | -$179.9M-37.8% | -$130.5M-17.9% | -$110.7M+7.0% | -$119.1M-57.0% | -$75.8M-123.4% | -$34.0M | N/A | -$10.3M |
| Interest Expense | $49.3M | $45.8M+22.5% | $37.4M+57.1% | $23.8M-4.7% | $25.0M-4.0% | $26.0M-4.0% | $27.1M+73.5% | $15.6M+527.6% | $2.5M | N/A | N/A | N/A | $1K | N/A | N/A | N/A |
| Income Tax | -$32K | $43K-24.6% | $57K-82.4% | $323K-12.5% | $369K+37.7% | $268K-13.3% | $309K+672.5% | $40K+53.8% | $26K-58.7% | $63K-54.7% | $139K+100.1% | -$118.1M-55.8% | -$75.8M-123.2% | -$33.9M | N/A | N/A |
| Net Income | -$224.7M | -$196.0M-156.5% | -$76.4M+46.6% | -$143.1M+13.4% | -$165.3M-33.2% | -$124.1M+36.8% | -$196.3M+1.7% | -$199.6M-11.9% | -$178.4M-38.3% | -$129.0M-17.7% | -$109.6M+7.3% | -$118.2M-56.0% | -$75.8M-123.2% | -$33.9M | N/A | -$10.3M |
| EPS (Diluted) | — | -$17.93 | -$14.00+25.5% | -$18.79 | -$2.02-22.4% | -$1.65+39.3% | -$2.72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KPTI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $108.4M-34.1% | $164.4M-31.6% | $240.4M-32.9% | $358.2M+17.3% | $305.3M-2.5% | $313.1M+6.1% | $295.0M-13.5% | $341.2M+89.2% | $180.3M-0.1% | $180.4M-16.3% | $215.4M-2.2% | $220.3M+39.3% | $158.2M+11969.1% | $1.3M | N/A |
| Current Assets | $103.1M-34.1% | $156.5M-33.1% | $233.9M-33.2% | $350.2M+27.1% | $275.6M-0.3% | $276.5M-0.7% | $278.6M-16.7% | $334.6M+125.4% | $148.4M+12.8% | $131.6M-25.9% | $177.6M-14.5% | $207.8M+31.5% | $158.0M+16457.2% | $954K | N/A |
| Cash & Equivalents | $60.5M-3.1% | $62.5M+19.6% | $52.2M-61.4% | $135.2M-29.0% | $190.5M+121.7% | $85.9M-33.3% | $128.9M+9.2% | $118.0M+71.1% | $69.0M+38.9% | $49.7M-14.9% | $58.4M-61.3% | $150.6M-3.4% | $156.0M+39791.0% | $391K-94.0% | $6.5M |
| Inventory | $4.0M-14.8% | $4.7M+55.7% | $3.0M-28.0% | $4.2M+2.9% | $4.1M+55.3% | $2.6M+664.2% | $346K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $401.3M+14.5% | $350.4M-7.0% | $376.6M+0.5% | $374.8M-2.6% | $385.0M+46.7% | $262.5M+7.1% | $245.2M+55.2% | $158.0M+210.9% | $50.8M+180.2% | $18.1M+6.2% | $17.1M+26.1% | $13.5M+311.4% | $3.3M-88.7% | $29.2M | N/A |
| Current Liabilities | $92.1M-0.2% | $92.3M+32.8% | $69.5M+5.4% | $65.9M-10.6% | $73.7M+22.4% | $60.2M+29.9% | $46.4M-1.2% | $46.9M-5.2% | $49.5M+200.2% | $16.5M+8.9% | $15.1M+23.0% | $12.3M+273.7% | $3.3M+70.6% | $1.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | $169.3M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$292.9M-57.5% | -$186.0M-36.6% | -$136.2M-717.8% | -$16.7M+79.1% | -$79.7M-257.6% | $50.5M+1.6% | $49.8M-72.8% | $183.2M+41.5% | $129.5M-20.2% | $162.2M-18.2% | $198.4M-4.1% | $206.8M+33.5% | $154.9M+655.8% | -$27.9M-120.4% | -$12.7M |
| Retained Earnings | -$1.8B-12.5% | -$1.6B-5.1% | -$1.5B-10.6% | -$1.3B-14.0% | -$1.2B-10.2% | -$1.1B-22.5% | -$873.3M-29.6% | -$673.7M-36.0% | -$495.3M-35.3% | -$366.1M-42.7% | -$256.5M-85.4% | -$138.3M-121.1% | -$62.6M | N/A | N/A |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
KPTI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$65.3M | -$75.4M+40.9% | -$127.5M-37.5% | -$92.7M+38.0% | -$149.6M-39.6% | -$107.1M+33.2% | -$160.2M+16.0% | -$190.8M-19.9% | -$159.1M-115.8% | -$73.7M+12.6% | -$84.4M+10.3% | -$94.0M-82.8% | -$51.4M-69.8% | -$30.3M | N/A | -$8.5M |
| Capital Expenditures | N/A | $0-100.0% | $142K | $0-100.0% | $118K-44.3% | $212K+46.2% | $145K-29.6% | $206K-91.3% | $2.4M+3711.3% | $62K-11.4% | $70K-95.1% | $1.4M-50.0% | $2.8M+4871.9% | $57K-52.9% | $121K-67.8% | $376K |
| Free Cash Flow | N/A | -$75.4M+40.9% | -$127.6M-37.6% | -$92.7M+38.0% | -$149.7M-39.5% | -$107.3M+33.1% | -$160.4M+16.0% | -$191.0M-18.3% | -$161.5M-118.9% | -$73.8M+12.6% | -$84.5M+11.5% | -$95.4M-75.8% | -$54.3M-78.9% | -$30.3M | N/A | -$8.9M |
| Investing Cash Flow | $3.0M | $43.4M-54.6% | $95.5M+1102.4% | $7.9M+107.6% | -$104.3M-173.5% | $141.8M+364.2% | -$53.7M-168.4% | $78.5M+172.9% | -$107.7M-729.3% | $17.1M-30.4% | $24.6M | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $78.6M | $30.0M-27.8% | $41.6M+3605.2% | $1.1M-99.4% | $193.7M+163.1% | $73.6M-57.2% | $172.1M+38.4% | $124.3M-60.7% | $316.1M+317.3% | $75.7M+48.0% | $51.2M | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KPTI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -62.1%+20.1pp | -82.2%+6.5pp | -88.7%+1.8pp | -90.5%-43.7pp | -46.8% | -159.0% | -462.8% | -593.0% | -8133.2% | -71903.9% | -47630.4% | -33120.5% | -8772.6% | N/A | -6783.5% |
| Net Margin | -134.2% | -52.6%+45.4pp | -98.0% | -105.2% | -59.1% | -181.6% | -488.1% | -588.1% | -8036.4% | -71153.9% | -47272.4% | -33090.4% | -8771.8% | N/A | -6783.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -388.3%+12.7pp | -401.0%-303.6pp | -97.4%+2.2pp | -99.6%-32.1pp | -67.5%-8.0pp | -59.6%-22.9pp | -36.6%-14.7pp | -21.9% | N/A | N/A |
| Return on Assets | -180.8%-134.3pp | -46.5%+13.0pp | -59.5%-13.4pp | -46.2%-5.5pp | -40.6%+22.1pp | -62.7%+5.0pp | -67.7%-15.4pp | -52.3%+19.3pp | -71.5%-10.8pp | -60.8%-5.9pp | -54.9%-20.5pp | -34.4%-12.9pp | -21.4% | N/A | N/A |
| Current Ratio | 1.12-0.6x | 1.70-1.7x | 3.37-1.9x | 5.31+1.6x | 3.74-0.9x | 4.59-1.4x | 6.01-1.1x | 7.13+4.1x | 3.00-5.0x | 7.99-3.7x | 11.74-5.2x | 16.89-31.1x | 47.98+47.5x | 0.49 | N/A |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 5.19+0.3x | 4.93+4.1x | 0.86+0.5x | 0.39+0.3x | 0.110.0x | 0.090.0x | 0.070.0x | 0.02 | N/A | N/A |
| FCF Margin | -51.6%+36.3pp | -87.9%-24.4pp | -63.5%+31.8pp | -95.3%-44.1pp | -51.1% | -148.4% | -467.1% | -532.3% | -4596.8% | -54844.8% | -38178.0% | -23703.5% | -7841.6% | N/A | -5871.7% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$292.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where Karyopharm Therapeutics Inc Ranks
Frequently Asked Questions
What is Karyopharm Therapeutics Inc's annual revenue?
Karyopharm Therapeutics Inc (KPTI) reported $146.1M in total revenue for fiscal year 2025. This represents a 0.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Karyopharm Therapeutics Inc's revenue growing?
Karyopharm Therapeutics Inc (KPTI) revenue grew by 0.6% year-over-year, from $145.2M to $146.1M in fiscal year 2025.
Is Karyopharm Therapeutics Inc profitable?
No, Karyopharm Therapeutics Inc (KPTI) reported a net income of -$196.0M in fiscal year 2025.
What is Karyopharm Therapeutics Inc's EBITDA?
Karyopharm Therapeutics Inc (KPTI) had EBITDA of -$90.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Karyopharm Therapeutics Inc's operating margin?
Karyopharm Therapeutics Inc (KPTI) had an operating margin of -62.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Karyopharm Therapeutics Inc's free cash flow?
Karyopharm Therapeutics Inc (KPTI) recorded an outflow of $75.4M in free cash flow during fiscal year 2025. This represents a 40.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Karyopharm Therapeutics Inc's operating cash flow?
Karyopharm Therapeutics Inc (KPTI) recorded an outflow of $75.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Karyopharm Therapeutics Inc's total assets?
Karyopharm Therapeutics Inc (KPTI) had $108.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Karyopharm Therapeutics Inc's capital expenditures?
Karyopharm Therapeutics Inc (KPTI) reported no capital expenditure during fiscal year 2025.
How much does Karyopharm Therapeutics Inc spend on research and development?
Karyopharm Therapeutics Inc (KPTI) invested $125.6M in research and development during fiscal year 2025.
What is Karyopharm Therapeutics Inc's current ratio?
Karyopharm Therapeutics Inc (KPTI) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
What is Karyopharm Therapeutics Inc's return on assets (ROA)?
Karyopharm Therapeutics Inc (KPTI) had a return on assets of -180.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is Karyopharm Therapeutics Inc's debt-to-equity ratio negative or not reported?
Karyopharm Therapeutics Inc (KPTI) has negative shareholder equity of -$292.9M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Karyopharm Therapeutics Inc's Altman Z-Score?
Karyopharm Therapeutics Inc (KPTI) has an Altman Z-Score of -23.95, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Karyopharm Therapeutics Inc's Piotroski F-Score?
Karyopharm Therapeutics Inc (KPTI) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Karyopharm Therapeutics Inc's earnings high quality?
Karyopharm Therapeutics Inc (KPTI) reported a net loss of $196.0M while operations used $75.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Karyopharm Therapeutics Inc cover its interest payments?
Karyopharm Therapeutics Inc (KPTI) reported an operating loss of $90.7M against $45.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Karyopharm Therapeutics Inc?
Karyopharm Therapeutics Inc (KPTI) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.